

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Clinical Practice – Surveillance Programme

Clinical guideline

CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care

Publication date

January 2012

Surveillance report for GE

February 2014

Key findings

			Potential impact on guidance	
			Yes	No
Evidence from Evidence Update			✓	
Feedback from Chair of the Evidence Update Advisory Group			✓	
Anti-discrimination and equalities considerations				✓
No update	Rapid update	Standard update	Transfer to static list	Change review cycle
✓				

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Clinical Practice – Surveillance Programme

Surveillance review of CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care

Background information

Guideline issue date: 2012

2 year review: 2014

NCC: NCGC

Current two year surveillance review

1. The Evidence Update on CG137: Epilepsy (expected publication date: February 2014) was used as the primary source of evidence for this surveillance review (search dates: June 2010 –September 2013). Clinical feedback on the surveillance decision for the guideline was obtained from the Chair of the Evidence Update Advisory Group.
2. The Evidence Update indicates that there is currently insufficient new evidence to invalidate the majority of the guideline recommendations. However, the Evidence Update has one area: adjunctive treatment for refractory focal epilepsy with new evidence which may impact current guideline recommendations. The 3 trials regarding perampanel which were identified in the Evidence Update, were not head to head trials, and it is unlikely that they would alter the conclusions of the existing model that supports the current recommendations. Hence an update in this area is not worthwhile at this time. A summary of the evidence is provided in the Evidence Update.
3. The Chair of the Evidence Update Advisory Group (and member of the original Guideline Development Group) felt that CG137 Epilepsy the majority of the guideline is up to date but the guideline could benefit from updating around adjunctive treatment for refractory focal epilepsy.

On-going Research

4. Not applicable.

Anti-discrimination and equalities considerations

5. None identified.

Implications for other NICE programmes

6. None identified.

Conclusion

7. Through the surveillance review of CG137, no new evidence which may potentially change the direction of guideline recommendations was identified.

Surveillance recommendation

8. GE is asked to consider the proposal to not update the guideline at this time. GE are asked to note that as a 2 year surveillance review this 'no to update' proposal will not be consulted on.

Mark Baker – Centre Director
Sarah Willett – Associate Director
Katy Harrison– Technical Analyst

Centre for Clinical Practice
February 2014

References

1. Aranda A, Foucart G, Ducassé JL et al. (2010) Generalized convulsive status epilepticus management in adults: a cohort study with evaluation of professional practice. *Epilepsia* 51: 2159–67
2. Baca CB, Vickrey BG, Caplan R et al. (2011) Psychiatric and medical comorbidity and quality of life outcomes in childhood-onset epilepsy. *Pediatrics* 128: e1532-e1543 [NIH Public Access author manuscript – full text]
3. Brigo F, Storti M, Del Felice A et al. (2012) IV Valproate in generalized convulsive status epilepticus: a systematic review. *European Journal of Neurology* 19: 1180–91
4. Campbell E, Devenney E, Morrow J et al. (2013) Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. *Epilepsia* 54: 165–71
5. Engel J, McDermott MP, Wiebe S et al. (2012) Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. *JAMA* 307: 922–30
6. French JA, Krauss GL, Biton V et al. (2012) Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. *Neurology* 79: 589–96 [NIH Public Access author manuscript – full text]
7. French JA, Krauss GL, Steinhoff BJ et al. (2013) Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305. *Epilepsia* 54: 117–25
8. Krauss GL, Serratoso JM, Villanueva V et al. (2012) Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. *Neurology* 78: 1408–15
9. Meador KJ, Baker GA, Browning N et al. (2010) Effects of breastfeeding in children of women taking antiepileptic drugs. *Neurology* 75: 1954–60
10. Meador KJ, Baker GA, Browning N et al. (2013) Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. *Lancet Neurology* 12: 244–52 [NIH Public Access author manuscript – full text]
11. Ng YT, Conry JA, Drummond R et al. (2011) Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. *Neurology* 77: 1473–81
12. Ryvlin P, Cucherat M, Rheims S (2011) Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. *Lancet Neurology* 10: 961–8
13. Sharma S, Sankhyan N, Gulati S et al. (2013) Use of the modified Atkins diet for treatment of refractory childhood epilepsy: a randomized controlled trial. *Epilepsia* 54: 481–6
14. Taylor RS, Sander JW, Taylor RJ et al. (2011) Predictors of health-related quality of life and costs in adults with epilepsy: a systematic review. *Epilepsia* 52: 2168–80
15. Vajda FJ, O'Brien TJ, Lander CM et al. (2013) Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. *Epilepsia* 54: 181–6